Global media also writes on failure of cloud-seeding in Delhi and the increasing demand for weight-loss drugs. FT interviews Sumant Sinha, founder of ReNew Energy.
Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and Wegovy, are expiring in nearly 100 nations.
India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.
Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in India by US based pharma giant Eli Lilly & Company.
Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended alongside a controlled diet and regular physical activity.
India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to transform access to weight-loss treatment.
The wealthy float above the crisis—insulated in air-purified cars, weekend getaways at farmhouses, and vacations timed perfectly to coincide with Delhi’s worst weeks.
ThePrint had previously reported that India & Russia are talking about 5 more regiments of the S-400, but no contracts are to be signed during the Russian president's visit.
The India-South Africa series-defining fact is the catastrophic decline of Indian red ball cricket where a visiting team can mock us with the 'grovel' word.
COMMENTS